Exact Sciences (EXAS) Misses Q4 EPS by 24c, Revenue Beats, Offers Guidance

Exact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($1.28), $0.24 worse than the analyst estimate of ($1.04). Revenue for the quarter came in at $473.8 million versus the consensus estimate of $449 million.

GUIDANCE:

Exact Sciences sees FY2022 revenue of $1.975-2.027 billion, versus the consensus of $1.99 billion.

• Screening revenue of $1,340-$1,367 million, including $40-$42 million from PreventionGenetics,
• Precision Oncology revenue of $595-$610 million, and
• COVID-19 testing revenue of $40-$50 million

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c
• Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c